Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

benzinga.com/analyst-stock-ratings/price-target/25/06/45890373/insmeds-pulmonary-hypertension-drug-data-exceeded-even-bullish-outlook-analyst

Insmed Incorporated (NASDAQ:INSM) on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension.
The study met its primary endpoint and all secondary efficacy…

This story appeared on benzinga.com, 2025-06-11 17:32:47.
The Entire Business World on a Single Page. Free to Use →